- Xyrem: Uses, Dosage, Side Effects, Warnings - Drugs. com
Xyrem (sodium oxybate) is an oral prescription solution that may be used to treat cataplexy or excessive daytime sleepiness (EDS) in adults and children aged 7 years and older with narcolepsy
- XYREM - Sodium Oxybate Treatment for Cataplexy and EDS in . . .
Learn about XYREM® (sodium oxybate oral solution), and how it can help your narcolepsy patients’ cataplexy and excessive daytime sleepiness (EDS) symptoms See XYREM® prescribing information BOXED Warning about serious side effects, CNS depression, misuse, and abuse
- Sodium oxybate: Dosage, Side Effects, Warnings - Drugs. com
Sodium oxybate is used to treat narcolepsy symptoms, such as cataplexy or excessive daytime sleepiness in adults and children aged 7 and older
- Sodium Oxybate (Xyrem) - Uses, Side Effects, and More
Find patient medical information for Sodium Oxybate (Xyrem) on WebMD including its uses, side effects and safety, interactions, pictures, warnings, and user ratings
- Effects of Oxybate on Sleep, Sleep Architecture, and . . .
Background: Sleep disturbances in narcolepsy encompass self-reported sleep quality, sleep architecture, and DNS DNS is associated with frequent sleep stage shifts and awakenings arousals on polysomnography Sodium oxybate (SXB; Xyrem ®), dosed twice nightly, is approved to treat excessive daytime sleepiness and cataplexy in patients with
- Sodium Oxybate (Xyrem): Narcolepsy Drug Side Effects Dosage
Xyrem (sodium oxybate) oral solution is indicated for the treatment of cataplexy in narcolepsy Xyrem (sodium oxybate) oral solution is indicated for the treatment of excessive daytime sleepiness (EDS) in narcolepsy
- Xyrem: Uses, Taking, Side Effects, Warnings - Medicine. com
Xyrem is a central nervous system (CNS) depressant used to treat cataplexy and excessive daytime sleepiness (EDS) in people with narcolepsy
- The Nightly Use of Sodium Oxybate Is Associated with a . . .
To further explore the effects of sodium oxybate (SXB) administration on nocturnal sleep in narcolepsy patients during a double-blind, placebo-controlled, parallel group study conducted with 228 adult patients with narcolepsy cataplexy in the United
|